PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2629.1003-008		1820,478	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION AN APPLICATION November 16, 2004 (Use several sheets if necessary)	I PIRST NAMED HAVE DIVION		FILING DATE April 8, 200)4
	EXAMINER Not Assigned	CONFI 8698	RMATION NO.	group 1654

 -			U.S. PA	TENT DOCU	MENTS			
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)		PUB	SSUE DATE / LICATION DATE IM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
w	AK	US 2003/0064929 A1		04/03/2003		Duranton et al.	al.	
								
	 							
				<u> </u>			=	
]	FOREIG	N PATENT DO	OCUMENTS			
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	MN	DATE 1-DD-YYYY	NAME OF PATENTER OF CITED DO		TRANSI YES	ATION NO
w) AL2	WO 90/04584	05/03/1990		BIOREX KUTATO FEJLESZTO KFT.			
	-		-	<u>.</u>				
	_		-					

Λ	
EXAMINER WILLIAM	DATE CONSIDERED OF / Le/ 157 5
@PFDesktop\:ODMA/MHODMA/HBSR03;iManage;\$10572;1	

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION August 31, 2004 FIRST NAMED INVENTOR Sudhir V. Shah FIRST NAMED INVENTOR April 8, 2004 FIRST NAMED INVENTOR April 8, 2004 Sudhir V. Shah CONFIRMATION NO. GROUP 1654	OIPE	ATTORNEY DOCKET NO.	APPI 10/	LICATION NO. 820,478	., <u>.</u>	Sheet 1 of 1
August 31, 2004 EXAMINER CONFIRMATION NO. 1654 Other several sheets if necessary) Other several sheets if necessary)	H 2009 4403;	72629.1003-008 FIRST NAMED INVENTOR Sudhir V. Shah		FILING DATI April 8, 2	2004	
	August 31, 2004 (Use several sheets if necessary)	EXAMINER Not Assigned		NON NO.		

			August 51, 200	- 13	Not Assigned		8698			
		(Use	several sheets if necessary)							
			u l	S. PA	TENT DOCUME	ENTS	 -			_
AM- REF. DOCUMENT NUMBER RNUMBER Number-Kind Code (if known)			ISSUE DATE / PUBLICATION DATE MM-DD-YYYY		NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		NT			
I. AL	NO.		Numoci-remo		08-04-1987			Green		
W) AE	4,6	84,482		09-10-1991			Suzuki		
N	AF	5,0	47,329					Martin et al.		
~	AG	6,2	06,849 B1		03-27-2001			Schwartz		
~	AH	6,3	383,817 B2		05-07-2002			Torti et al.		
	AJ	+-	589,966 B1		07-08-2003			Ranganathan	et al.	
<u> </u>	I AJ		707 297 P2		03-16-2004		لاسيي	144		
	1 41	10,	F	OREIG	N PATENT DO	CUMENTS				
	T		DOCUMENT NUMBER Country Code-Number-Kind Code	м	DATE IM-DD-YYYY	NAME OF OF	PATENTE CITED D	E OR APPLICANT OCUMENT	TRANSLA' YES	NO
Å	1_		(if known)	-)9-21-2000	Aripkoho	dzhaeva	· ·		X
0	MA	P	WO 00/54784	Conten Pha		armace	naceuticals Co., Ltd X			
0	_ A	AQ JP 05000949 A		1	Dai Ichi Seiyaku Co			Co., Liu.	(Abstract)	<u> </u>
			OTHER DOCUME	NTS (I	ncluding Author,	Title, Date, F	ertinent	Pages, Etc.)		
	A A	W5	Fernández-Real, J.M., et al., "(2354, 2002	Cross-	Talk Between	Iron Metab	olism ar	nd Diabetes, Die	emand Can	
	1	XS	Nitenberg, A., et al., "Coronal Restored by Inhibition of Iron Patients," Diabetes, 51:813-8	-Catal 18, 20	yzed Formatio	n of Oxyge	n Free 1	Cadicais in 1990		
ľ		ــــــــــــــــــــــــــــــــــــــ								

EXAMINER OF ALL X	DATE CONSIDERED OF LY LOS
@PFDesktopl. ODMA/MHODMA/HBSR05;iManage;470812;1	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ΑТ		RNI			CKET	NO
26	529).10	00	3-(800	

FIRST NAMED INVENTOR Sudhir V. Shah

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	ATION NO		
do 1	A.P	WO 88/04925	07-14-1988	The Administrators of the Tu- Lane Educational Fund	·			
ا (ر	AQ	WO 98/09626	03-12-1998	Medinox, Inc.				
						_		
						-		
				 				

EXAMINER ANDUM	DATE CONSIDERED 62/15/107
ODER ODIA A GLODIA A BERNA	

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;465568;

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2629.1003-008

FIRST NAMED INVENTOR Sudhir V. Shah

	U.S. PATENT DOCUMENTS								
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT					
μ	AA	5,047,421	09-10-91	Green					
a	AB	5,721,209	02-24-98	Horwitz et al.					
~	AC	5,811,127	09-22-98	Milstein et al.					
6	AD	5,091,180	02-25-92	Walker et al.					

		3,071,100	02-23-92	waiker et al.		
		F	OREIGN PATENT DO	CUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
۶	AL /	WO 94/01770 A	01-20-1994	Shapiro, Svetlana Borisovna and Aleksandrovskaya, Tamara Nikolayevna	X	
~	AM	DE 40 08 323 A	09-19-1991	Knoll AG	X	
6	AN	WO 00/13706 A	03-06-2000	Henry Ford Health System		
٢	AO	WO 91/07956 A	06-13-1991	Knoll Aktiengesellschaft	-	x
					• . :	
- J-J'-	ļ					

EXAMINER (ulu	Ms	DATE CONSIDERED	/ 23/	1200 5
		//			
@PEDeskion\"ODMA/MHO	DMA/UDSDOS: Manager	465305-1			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2629.1003-008

FIRST NAMED INVENTOR Sudhir V. Shah

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
W	AR	Sumboonnanonda, A., et al., "Renal tubular function in β-thalassemia", Pediatr Nephrol, 12:280-283.						
1	AS	Ong-ajyooth, L., et al., "Renal Function in Adult Beta-Thalassemia/Hb E Disease", Nephron, 78:156-161 (1998).						
2	AT	Guasch, A., et al., "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", J Am Soc Nephrol, 10:1014-1019 (1999).						
~	ΑÜ	Loebstein, R., et al., "Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia", Diabetes Care, 21(8):1306-1309 (1998).						
6	AV	Ongajyooth, L., et al., "Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).						
~	AW	Aoki, R.Y., et al., "Microalbuminuria in Sickle Cell Disease", Brazilian J Med Biol Res, 23:1103-1106 (1990).						
5	AX	Katopodis, K.P., et al., "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", Journal of Nephrology, 10(3):163-167 (1997).						
<i></i>	AY	Pham, PT.T., et al., "Renal abnormalities in sickle cell disease", Kidney International, 57:1-8 (2000).						
0	AZ	Kontoghiorghes, G.J., et al., "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", Inorganica Chimica Acta., 136:L11-L12 (1987).						
7	AR2	Falk, R.J., et al., "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Convertng Enzyme", The New England Journal of Medicine, 326(14):910-915 (1992).						
0	AS2	Guasch, A., et al., "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", Kidney International, 51:826-833 (1997).						
7	AT2	Cianciulli, P., et al., "Early detection of nephrotoxic effets in thalassemic patients receiving desferrioxamine therapy", Kidney International, 46:467-470 (1994).						
V	AU2	Ueda, N., et al., "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", Kidney International, 49:370-373 (1996).						

EXAMINER HULL du	DATE CONSIDERED 2/1=/1005	
0000 1		_

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2629.1003-008

FIRST NAMED INVENTOR Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
N	AV2	Savill, J., et al., "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 nd ed., pages 404-439, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).				
N	AW2	Ueda, N., et al., "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", Kidney: A Current Survey of World Literature, 6:143-146 (1997).				
ν	AX2	Boyce, N.W., et al., "Hydroxyl radical mediation of immune renal injury by desferrioxamine", Kidney International, 30:813-817 (1986).				
~	AY2	Baliga, R., et al., "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", J Am Soc Nephrol, 7(8):1183-1188 (1996).				
K	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).				
~	AR3	Thakur, V., et al., "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", Kidney International, 34:494-499 (1988).				
~	AS3	Nankivell, B.J., et al., "The Role of Tubular Iron Accumulation in the Remnant Kidney", J Am Soc Nephrol, 4(8):1598-1607 (1994).				
~	AT3	Alfrey, A.C., et al., "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", Kidney International, 36:753-759 (1989).				
٢	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 nd ed., pages 1749-1788, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).				
N	AV3	Howard R.L., et al., "Urinary albumin, transferrin and iron excretion in diabetic patients", International Society of Nephrology, 40:923-926 (1991).				
Ç	AW3	Olivieri, N.F., et al., "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", The New England Journal of Medicine, 918-922 (1995).				
7	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", American Journal of Physiology, 263(4):F637-F641 (1992).				

EXAMINER HILL UICA	DATE CONSIDERED OLASITA
@PFDesktop\::ODMA/MHODMA/HBSR05:iManage:465305:1	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2629.1003-008

FIRST NAMED INVENTOR Sudhir V. Shah

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
dr AY3	Wu, Z-L, et al., "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," Renal Failure, 16(4): 471-480 (1994).					
N AZ3	Baliga, R., et al., "In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity," Kidney International, 53(2): 394-401 (February 1998).					
AR4	Harris, D., et al., "Mitrochondrial Function in Rat Renal Cortex in REsponse to Proteinuria and Iron," Clinical and Experimental Pharmacology and Physiology 24:916-922 (December 1997).					
N AS4	Walker, P.D., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats," J Clin Invest 81:334-341 (1988).					
AT4	Shah, S.V., et al., "Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure," Am J Physiol 255, (Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).					
AU4	Baliga, R., et al., "Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys," Biochem J 291(3):901-905 (1993).					
AV4	Kontoghiorghese, G.J., et al., "Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one," Arzneim-Forsh/Drug Res. 44(1):522-526 (1994).					
AW4	Baliga, R., et al., "Oxidant Mechanisms in Toxic Acute Renal Failure," Drug Metabolism Reviews 31(4):971-991 (1999).					
M AX4	Walker, P.D., et al., "Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria," Am J Physiol 253:C495-C499 (1987).					
N AY4	Walker, P.D., et al., "Hydrogen Peroxide Cytotoxicity in LLC-PK, Cells: A Role for Iron," Kidney Int 40:891-898 (1991).					
AZ4	Abul-Ezz, S.R., et al., "Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure," Proc Natl Acad Sci 88:9833-9837 (1991).					
ARS	Ueda, N., et al., "Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria," Am J Physiol 265(3 Pt. 2):F435-F439 (1993).					
AS5	Baliga, R., et al., "Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure," Kidney Int 49:362-369 (1996).					

EXAMINER 9	M	△ ✓	DAT	E CONSIDERED	12005		
@PFDeskton\: ODMA/M	HODMA/HBSROS-IN	fanage:465305:1		$t \rightarrow t$			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 8, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2629.1003-008

FIRST NAMED INVENTOR Sudhir V. Shah

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
V	AT5	Baliga, R., et al., "Role of Cytochrome P-450 as a Source of Catalytic Iron in Cisplatin-Induced Nephrotoxicity," Kidney Int 54:1562-1569 (1998).					
4	AU5	Hanss, B.G., et al., "The Iron Chelator Deferoxamine Prevents Contrast Media Induced Acute Renal Failure in the Rabbit." Presented at the American Society of Nephrology, 23 rd Annual Meeting, JASN 1(4):612 (1990) (abstract).					
W	AV5	Baliga, R., et al., "Role of Iron in Cisplatin-Induced Acute Renal Failure in Rats," J Am Soc Nephrol 7(9):1822 (1996) (abstract).					

EXAMINER 2	MI	DATE CONSIDERED Day / 4 / / wy	
@PFDesktop\::ODMA/MHOD	MA/HBSR05;iManage;465305;1		